Skip to main content

BioAge Labs, Inc.

corporate_fare Company Profile

BioAge Labs, Inc.

BIOA·NASDAQ·Life Sciences·CIK 0001709941

We are a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. Our technology platform and differentiated human datasets help us identify promising targets based on insights into molecular changes that drive aging. In January 2025, we announced our lead program, BGE-102, a potent, structurally novel, orally available, brain-penetrant small-molecule NLRP3 inhibitor. BGE-102 has a distinct mechanism and binding site from other NLRP3 inhibitors in development, with issued patents covering both its composition and claims for its unique binding site. In December 2025, we announced that BGE-102 was well-tolerated in Single Ascending Dose (SAD) and initial Multiple Ascending Dose (MAD) cohorts, with a pharmacokinetic profile supporting once-daily oral dosing, strong target engagement, and high brain penetration. We intend to advance BGE-102 in two therapeutic areas: cardiometabolic disease and ophthalmology. Our first therapeutic area for BGE-102 is cardiometabolic disease, focusing on atherosclerotic cardiovascular disease (ASCVD) risk reduction. Chronic systemic inflammation, measured by high-sensitivity C-reactive protein (hsCRP), is an independent risk factor for cardiovascular events not adequately addressed by current lipid-lowering and antihypertensive therapies. In January 2026, we announced additional positive interim Phase 1 data, demonstrating potential for hsCRP reduction in participants with elevated cardiovascular risk. In obese participants with elevated hsCRP, BGE-102 showed an 86% median reduction in hsCRP at Day 14, with 93% of participants achieving hsCRP levels below 2 mg/L. We anticipate full Phase 1 SAD / MAD clinical trial results in the first half of 2026. Our second therapeutic area for BGE-102 is ophthalmology, with diabetic macular edema (DME) as our first proof-of-concept indication.

BioAge Labs, Inc. (NASDAQ:BIOA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 18 items for BIOA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 18 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for BIOA spans 10-Q, 8-K, DEF 14A, 10-K.

Recent high-impact activity:

  • BioAge 10-Q: Q3 Net Loss Widens to $33.5M as BGE-102 Costs Climb; $352.3M Cash Funds Runway Through 2029
  • BioAge Posts Wider Q3 Loss as BGE-102 Trials Advance; QUELL-CV Data Due Q4
  • BioAge Doses First Patient in Phase 2 DME Trial for Oral NLRP3 Inhibitor
  • BioAge Labs Q2 2026: $381M Cash, BGE-102 Phase 2 Underway, Insiders Adopt 10b5-1 Plans
  • BioAge Labs Q2 2026: $381M Cash Funds Pipeline Through 2029, Phase 2 Data in H2 2026

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$8.99M
Net Income
-$80.61M
Diluted EPS
-$2.24
Op. Cash Flow
-$81.63M
Free Cash Flow
-$82.35M
Operating Income
-$92.78M
Cash & Equivalents
$188.89M
Total Debt
$2.65M
Debt / Equity
0.01×
Net Margin
-8.96×
Shares Outstanding
37.39M sh
Source: 10-K · filed 2026-03-24 · accession 0001193125-26-120873

Short Interest & Short Volume

4.34 days to cover

FINRA reported short interest of 3,725,017 shares in BIOA as of the October 30, 2026 settlement, a 8.6% increase from the prior period — about 4.3 days to cover at its recent average daily volume. On November 20, 2026, 57.7% of BIOA volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)3,725,017 shares as of October 30, 2026
Change vs prior period▲ 8.6%
Days to cover4.34 at avg daily volume of 857,733
Daily short volume (FINRA facilities)57.7% of 248,223 shares on November 20, 2026
5-day average short volume58.4%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with B →
$4.3 +0.47% today
52-week range · as of 2026-11-05 $4.3 – $25.95
Market cap
$196.7M
Volume
632.1K (0.9× avg)
3-mo avg 717.1K
Live data · 2026-11-21 06:09 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed BIOA - Latest Insights

BIOA
Nov 05, 2026, 4:40 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $5.48
Real-time Price: $4.30 info
Change: -$1.18 (-22%) info
Market Cap: $196.702M info
BIOA
Nov 05, 2026, 4:30 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $5.48
Real-time Price: $4.30 info
Change: -$1.18 (-22%) info
Market Cap: $196.702M info
BIOA
Sep 08, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $9.75
Real-time Price: $4.30 info
Change: -$5.45 (-56%) info
Market Cap: $196.702M info
BIOA
Aug 05, 2026, 5:00 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $10.98
Real-time Price: $4.30 info
Change: -$6.68 (-61%) info
Market Cap: $196.702M info
BIOA
Aug 05, 2026, 4:55 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $10.98
Real-time Price: $4.30 info
Change: -$6.68 (-61%) info
Market Cap: $196.702M info
BIOA
Jul 31, 2026, 1:24 PM EDT
Source: Benzinga
Importance Score:
8
Price at Filing: $9.58
Real-time Price: $4.30 info
Change: -$5.28 (-55%) info
Market Cap: $196.702M info
BIOA
Jun 16, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $19.84
Real-time Price: $4.30 info
Change: -$15.54 (-78%) info
Market Cap: $196.702M info
BIOA
May 08, 2026, 9:09 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $17.72
Real-time Price: $4.30 info
Change: -$13.42 (-76%) info
Market Cap: $196.702M info
BIOA
May 08, 2026, 9:05 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $17.72
Real-time Price: $4.30 info
Change: -$13.42 (-76%) info
Market Cap: $196.702M info
BIOA
Apr 21, 2026, 4:05 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $19.61
Real-time Price: $4.30 info
Change: -$15.31 (-78%) info
Market Cap: $196.702M info
BIOA
Mar 24, 2026, 9:15 AM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $18.53
Real-time Price: $4.30 info
Change: -$14.23 (-77%) info
Market Cap: $196.702M info
BIOA
Mar 24, 2026, 9:10 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $18.59
Real-time Price: $4.30 info
Change: -$14.29 (-77%) info
Market Cap: $196.702M info
BIOA
Mar 24, 2026, 9:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $18.60
Real-time Price: $4.30 info
Change: -$14.30 (-77%) info
Market Cap: $196.702M info
BIOA
Jan 22, 2026, 4:34 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $19.98
Real-time Price: $4.30 info
Change: -$15.68 (-78%) info
Market Cap: $196.702M info
BIOA
Jan 22, 2026, 4:32 PM EST
Filing Type: 424B5
Importance Score:
7
Price at Filing: $19.98
Real-time Price: $4.30 info
Change: -$15.68 (-78%) info
Market Cap: $196.702M info
BIOA
Jan 20, 2026, 4:01 PM EST
Filing Type: 424B5
Importance Score:
8
Price at Filing: $20.00
Real-time Price: $4.30 info
Change: -$15.70 (-78%) info
Market Cap: $196.702M info
BIOA
Jan 20, 2026, 9:05 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $19.66
Real-time Price: $4.30 info
Change: -$15.36 (-78%) info
Market Cap: $196.702M info
BIOA
Jan 12, 2026, 9:10 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $14.49
Real-time Price: $4.30 info
Change: -$10.19 (-70%) info
Market Cap: $196.702M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets